B-rayz AG received CE mark for its Data Adaptive Neural Artificial Intelligence (DANAI) technology that helps clinicians with breast cancer detection. The company hopes that DANAI, which introduces a custom AI-based framework that can adapt to clinicians needs and grow smarter in the process, will revolutionize the diagnostic landscape for breast imaging and transform the lives of millions of women.
Chinese researchers have presented data on a novel six-gene prognostic risk model for breast cancer based on data from the The Cancer Genome Atlas (TCGA) database.
DNA replication stress induced by oncogenes is a known driver of chromosomal instability, which is associated with poor prognosis in several cancer types.
Olema Pharmaceuticals Inc. has advanced its program targeting KAT6, an epigenetic target dysregulated in breast and other cancers, with the selection of a development candidate, OP-3136. The orally bioavailable, potent KAT6A/B-selective inhibitor has been developed by Olema in collaboration with Aurigene Oncology Ltd.
Hinova Pharmaceuticals Inc. has divulged proteolysis targeting chimeric (PROTAC) compounds comprising a protein cereblon (CRBN) binding moiety covalently bound to an estrogen receptor (ER)-targeting moiety through a linker.
Researchers from Third Military Medical University of the Chinese PLA have published data from a study that aimed to investigate the biological functions and molecular mechanisms of tandem C2 domains, nuclear (TC2N) in the development and progression of breast cancer.
Synnovation Therapeutics Inc. has identified phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS), congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities.
Researchers from Mbrace Therapeutics Inc. presented the discovery and preclinical evaluation of MBRC-101, a novel antibody-drug conjugate (ADC) targeting the membrane-associated tyrosine kinase receptor EphA5, being developed for the treatment of cancer.